Structured scientific exchange with 120 Tier 1 thoracic oncologists across five launch markets.
Budget vs actual spend
$418k
of $620k planned (67%)
Spend is in line with or behind elapsed time. Elapsed: 73%.
Late-by counts days between due date and completion, or due date and today for open milestones.
| Milestone | Due | Completed | Status | Timing | Late by | Evidence |
|---|---|---|---|---|---|---|
| Stakeholder mapping complete | 28 Feb 2026 | 25 Feb 2026 | Completed | Completed on time | — | Tier list approved by GML |
| H1 engagement target (60% coverage) | 30 Jun 2026 | 28 Jun 2026 | Completed | Completed on time | — | Coverage report 63% |
| ESMO 2026 meetings | 18 Oct 2026 | — | In progress | Upcoming | — | — |
| H2 engagement target (85% coverage) | 15 Dec 2026 | — | Planned | Upcoming | — | — |
Insights routed to this initiative.
Elderly / ECOG 2 patients: gap in current materials reported by thoracic medical oncologist (DE).
Education need · 14 Apr 2026
Actions whose result record is this initiative.
No actions reference this initiative as their result.
Competitor TIGIT class scepticism reduces KOL willingness to adopt chemotherapy-free regimen.
P 3 × I 3 = 9 · Scientific · Dr. Priya Raman · due 31 Oct 2026
Over-contact of Tier 1 US oncologists (some engaged 6+ times in H1) risks stakeholder fatigue.
P 2 × I 2 = 4 · Stakeholder · James Whitfield · due 31 Oct 2026
Same objective (SO-VTX-01)
Same objective (SO-VTX-01)
Same objective (SO-VTX-01)
No tasks are linked to this initiative
No audit events for this record
Audit events are written when the record is created, changed, approved, signed or exported.
Data lineage